Adaptimmune Therapeutics PLC (ADAP)
0.6616
+0.02
(+3.93%)
USD |
NASDAQ |
Nov 22, 16:00
0.66
0.00 (0.00%)
After-Hours: 20:00
Adaptimmune Therapeutics Cash from Investing (Quarterly): -66.02M for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -66.02M |
| June 30, 2024 | -0.743M |
| March 31, 2024 | -0.358M |
| December 31, 2023 | 68.20M |
| September 30, 2023 | 57.31M |
| June 30, 2023 | 2.694M |
| March 31, 2023 | 48.34M |
| December 31, 2022 | 20.95M |
| September 30, 2022 | 28.85M |
| June 30, 2022 | 44.11M |
| March 31, 2022 | -4.775M |
| December 31, 2021 | -28.49M |
| September 30, 2021 | 34.85M |
| June 30, 2021 | 47.68M |
| March 31, 2021 | 21.76M |
| December 31, 2020 | 7.608M |
| September 30, 2020 | -27.58M |
| June 30, 2020 | -187.00M |
| March 31, 2020 | -71.95M |
| Date | Value |
|---|---|
| December 31, 2019 | 23.68M |
| September 30, 2019 | 35.04M |
| June 30, 2019 | 18.56M |
| March 31, 2019 | 17.66M |
| December 31, 2018 | -52.41M |
| September 30, 2018 | 0.942M |
| June 30, 2018 | 20.37M |
| March 31, 2018 | 13.64M |
| December 31, 2017 | -40.01M |
| September 30, 2017 | 9.751M |
| June 30, 2017 | -73.18M |
| March 31, 2017 | -22.64M |
| December 31, 2016 | 16.96M |
| September 30, 2016 | 5.743M |
| June 30, 2016 | 5.617M |
| March 31, 2016 | -10.56M |
| September 30, 2015 | -9.862M |
| December 31, 2014 | -26.18M |
| September 30, 2014 | -0.5278M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-187.00M
Minimum
Jun 2020
68.20M
Maximum
Dec 2023
0.9558M
Average
14.28M
Median
Cash from Investing (Quarterly) Benchmarks
| Biodexa Pharmaceuticals PLC | -- |
| NuCana PLC | -0.0053M |
| Autolus Therapeutics PLC | -9.589M |
| TC BioPharm (Holdings) PLC | -0.0071M |
| Verona Pharma PLC | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -54.45M |
| Cash from Financing (Quarterly) | 25.00M |
| Free Cash Flow | -56.05M |
| Free Cash Flow Per Share (Quarterly) | -0.2146 |
| Free Cash Flow to Equity (Quarterly) | -79.80M |
| Free Cash Flow to Firm (Quarterly) | -54.89M |
| Free Cash Flow Yield | -34.41% |